• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
VTVT

VTVT

vTv Therapeutics Inc.

NASDAQHealthcareBiotechnologyUS

USD32.94

-0.06 (-0.18%)

Rating:B-

Company Profile

CEO

Paul J. Sekhri

IPO Date

2015-07-30

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$33.23

Prev. Close

$33.00

Day Low

$32.68

Day High

$33.37

52W Low

$14.00

52W High

$44.00

Market Cap

$0.09B

Volume

0.02M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

49.1%

Avg Negative

2.1%

Avg Neutral

48.6%

News Feed

vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737

GlobeNewsWire·6/29/2021·↑ positive

vTv Therapeutics Shares Jump On Out-Licensing Agreement For Azeliragon In Cancer Settings

Benzinga·6/22/2021·↑ positive

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

GlobeNewsWire·6/22/2021·↑ positive

What Are Penny Stocks? 4 to Buy [Or Sell] In 2021

PennyStocks·6/10/2021·↓ negative

VTv Therapeutics (VTVT) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research·5/5/2021·↑ positive

vTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug

Zacks Investment Research·4/14/2021·↑ positive

VTVT Stock: The FDA News Sending vTv Therapeutics Soaring Today

InvestorPlace·4/13/2021·↑ positive

VTVT Stock: Over 15% Increase Pre-Market Explanation

Pulse2·4/13/2021·↑ positive

vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes

GlobeNewsWire·4/13/2021·↑ positive

TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin

GlobeNewsWire·4/12/2021·↑ positive